Paxlovid reduced the risk of hospitalization or death by 89 percent in a phase 3 trial, according to Pfizer. On Nov. 16, the company applied for emergency use authorization from the FDA for the pill.
Pfizer’s application comes about a month after Merck asked the FDA for emergency use authorization of molnupiravir, the COVID-19 antiviral pill it is developing with Ridgeback Biotherapeutics. The U.S. signed a deal with Merck in June to purchase 1.7 million courses of molnupiravir for $1.2 billion if it’s authorized by the FDA.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
